President Donald Trump is moving fast with his direct-to-customer pharmaceutical venture. On Friday, he shared from the Oval Office that he struck a deal with AstraZeneca to offer the US a "most-favored-nation" drug pricing policy that would lower prescription costs.As part of the deal, AstraZeneca has pledged to invest $50 billion in the US over the next five years in research and development of new drugs and onshore manufacturing. The company has also committed to offering prices to Medicaid patients tha ...